Del Rivero, J., Perez, K., Geyer, S. M., Khalil, M. F., Vijendran, A., Kordaris-Corkill, A., … O’Reilly, E. M. (2023). Alliance A021804: A prospective, multi-institutional phase II trial evaluating temozolomide versus temozolomide and olaparib for advanced pheochromocytoma and paraganglioma. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 41).

Del Rivero, Jaydira, Kimberly Perez, Susan Michelle Geyer, Maged F. Khalil, Aishwarya Vijendran, Andrea Kordaris-Corkill, Ardaman Shergill, et al. “Alliance A021804: A prospective, multi-institutional phase II trial evaluating temozolomide versus temozolomide and olaparib for advanced pheochromocytoma and paraganglioma.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 41, 2023.

Del Rivero J, Perez K, Geyer SM, Khalil MF, Vijendran A, Kordaris-Corkill A, et al. Alliance A021804: A prospective, multi-institutional phase II trial evaluating temozolomide versus temozolomide and olaparib for advanced pheochromocytoma and paraganglioma. In: JOURNAL OF CLINICAL ONCOLOGY. 2023.

Del Rivero, Jaydira, et al. “Alliance A021804: A prospective, multi-institutional phase II trial evaluating temozolomide versus temozolomide and olaparib for advanced pheochromocytoma and paraganglioma.” JOURNAL OF CLINICAL ONCOLOGY, vol. 41, no. 16, 2023.

Del Rivero J, Perez K, Geyer SM, Khalil MF, Vijendran A, Kordaris-Corkill A, Shergill A, Spencer KR, Soares HP, Lopez CD, Nixon AB, Dueck AC, Meyerhardt JA, O’Reilly EM. Alliance A021804: A prospective, multi-institutional phase II trial evaluating temozolomide versus temozolomide and olaparib for advanced pheochromocytoma and paraganglioma. JOURNAL OF CLINICAL ONCOLOGY. 2023.